NCT05001451View on ClinicalTrials.gov

Study of GDX012 in Patients With MRD Positive AML

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 13, 2021

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

GDX012 Suspension for IV Infusion

"Biological: GDX012 Suspension for IV Infusion (single dose) following chemotherapy for lymphodepletion.~Drug: Fludarabine; chemotherapy for lymphodepletion~Drug: Cyclophosphamide; chemotherapy for lymphodepletion"

Trial Locations (1)

91010

City of Hope, Duarte

Sponsors
All Listed Sponsors
lead

GammaDelta Therapeutics Limited

INDUSTRY